Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer - On Going Clinical Trials for Prostate Cancer Drugs

Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase IV

Diagnostic, Treatment

Active

18 and over

Pharmaceutical / Industry

CZOL446GDE22
NCT00391690

Trial Description

Summary

It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer. The usefulness in monitoring zoledronic acid therapy in patients who have developed bone metastases will also be assessed.

Eligibility Criteria

Inclusion criteria

Patients with histologically confirmed diagnosis of prostate cancer who have not yet developed bone metastases
Prostate cancer patients with a rise in PSA under hormone therapy.
PSA criteria:

Patients who have undergone prostatectomy: any rise in PSA or
Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month. The first measurement must occur one month after the reference value and must be above the reference value. The second confirmatory measurement taken one month after the first measurement must be greater than the first measurement.
Previous chemotherapy or radiotherapy must have been performed ≥ 8 weeks prior to study entry.
Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day)
Adequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value
Age: ≥ 18 years
Patient has given written informed consent prior to any study-specific procedures. Patients with psychiatric or addictive disorders which prevent them from giving their informed consent must not enter the study.
Exclusion criteria

Prior treatment with a bisphosphonate
Abnormal renal function as evidenced by a calculated creatinine clearance < 30 ml/minute.
Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/L) or ≥ 12.0 mg/dl (3.00 mmol/L).
Patients with clinically symptomatic brain metastases
History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism
Severe physical or psychological concomitant diseases that might impair compliance with the provisions of the study protocol or that might impair the assessment of drug or patient safety, e.g. clinically significant ascites, cardiac failure, NYHA III or IV, clinically relevant pathologic findings in ECG
Known hypersensitivity to zoledronic acid or other bisphosphonates
Use of other investigational drugs 30 days prior to the date of randomization
Known history or present abuse of alcohol or drugs
Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study
Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
Other protocol defined inclusion/exclusion criteria may apply.

Trial Contact Information

Trial Lead Organizations/Sponsors

Novartis Pharmaceuticals Corporation

Novartis Principal Investigator

Novartis Ph: 41 61 324 1111

Trial Sites